At this point our work is unable to address the dosage and timing of Smn expression necessary to alleviate postnatal SMA disease, which is the time period when all, but the very most severely affected, SMA patients present with symptoms. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.